Orally Disintegrating Tablets Market Size, share | Forecast 2031

Report Description

Orally Disintegrating Tablets Market Outlook 2031:

The Global Orally Disintegrating Tablets Market size was valued at USD 15.92 Billion in 2022 and is projected to reach USD 38.09 Billion by 2031, expanding at a CAGR of 10.18% during the forecast period 2023 - 2031. The demand for orally disintegrating tablets is growing as ageing population due to increased life expectancy in rising in many countries.

Moreover, Growing awareness among people regarding the availability of advance therapies is expected to boost the demand for advanced dosage form in developing countries. Additionally, Growing demand for multivitamins is expected to create lucrative opportunities for manufacturers in the market.

Get Free Sample Report

Orally Disintegrating Tablets Market Dynamics

Aging population is increasing due to rising life expectancy. Moreover, availability of advance medical facilities and advancements in medical science have increased the survival rate of people suffering from chronic diseases. Oral disintegrating tablets is an ideal solution for the elderly, which helps them to complete a drug course. This, in turn, is expected to propel the orally disintegrating tablets market growth.

Moreover, ODTs are suitable dosage forms prescribed for mentally disabled people, as compared to other dosage forms. It is easy to guide such people to take this dosage form, as it has fast onset of action, which provides them quick relief. Growing adoption of oral disintegrating tablets for the treatment of various conditions in mentally disabled is expected to boost the orally disintegrating tablets  market.

Furthermore, People suffering from various diseases such as Parkinson’s, Alzheimer's, lung diseases, kidney diseases, diabetes, stroke, heart diseases, and allergies, and GI disorders need to take various medications for a long period of time. Doctors prescribe oral medications to patients for post-operative care. Oral disintegrating tablets are ideal solutions for people, which disintegrates quickly and provides desired therapies with high patient compliance.

Oral route of administration is convenient and acceptable dosage form for patients and physicians. Oral route administration with fast onset of action boosts the demand for ODT, which has ability to dissolve within a minute. These factors are expected to boost the Oral disintegrating tablets market growth.

However, Product recalls of ODTs by some manufacturers due to particular reasons is expected to hamper the market. For example, Impax Laboratories recalled one lot of lamotrigine orally disintegrating tablet 200 mg indicated for the treatment of epilepsy or bipolar disorders. Such increase in product recalls is expected to hinder the market.

Additionally, ODTs can cause various side effects such as headaches, constipation, weakness, tiredness, dizziness, chills, loss of coordination, and drowsiness. In some conditions, it is important to inform the physician about other medications, if a person is taking along with a prescribed treatment to avoid the drug interactions, as it can led to serious side-effects.

Rising adoption of technologically advanced products and dosage forms for advanced treatment options in developing economies are expected to boost the demand for ODTs during the forecast period. Access to healthcare and improving the quality of care in developing countries are expected to create lucrative opportunities for manufacturers in these countries.

Scope of Orally Disintegrating Tablets Market Report 

Orally Disintegrating Tablets Market Segmental Outlook

Drug Class Segment

On the basis of drug class, the orally disintegrating tablets market is divided into anti-psychotics, anti-epileptic’s, CNS stimulants, anxiolytics, anti-parkinsonian drugs, anti-hypertensive, NSAIDS, anti-allergy drug, proton pump inhibitor, vaccine ODT, and others. The anti-psychotics segment is expected to hold xx% share of the market in 2020. The anti-parkinsonian drugs segment is anticipated to expand at a CAGR of xx% during the forecast period.

Growing prevalence of psychotic disorder such as schizophrenia and bipolar disorder is projected to increase the demand for anti-psychotic drugs. Moreover, growing prevalence of Parkinson is expected to boost the demand for anti-parkinsonian drugs. ODT prescribed in the drugs class including anti-psychotics and anti-parkinsonian drugs. ODT is a widely preferred dosage form, as it provides fast effect owing to its quick disintegration, thus leading to high patient compliance.

Get Free Sample Report

Disease Indication Segment

Based on disease indication, the Oral disintegrating tablets market share is segregated into central nervous system diseases (CNS), gastrointestinal (GI) diseases, cardiovascular (CVS) diseases, allergy, and others. The central nervous system diseases segment is estimated to account for significant market share in 2020, owing to increasing prevalence of CNS diseases globally.

The cardiovascular (CVS) diseases segment is anticipated to expand at an accountable CAGR of during the forecast period. Growing prevalence of CNS and CVS diseases is expected to boost the demand for oral disintegrating tablets.

Get Free Sample Report

Regional Outlook

Asia Pacific is expected to remain a highly attractive region for the orally disintegrating tablets market and is projected to expand at a high CAGR during the forecast period. The region is expected to dominate the global market, in terms of value and volume, due to the use of ODTs to reduce the prevalence of various disorders such as CND, GI disorders, CVDs, and allergies.

Growing population in the region and large presence of key players operating the market are major factors that are expected to increase the demand for ODTs in the region. High patient compliance and awareness among patients about availability of such dosage forms and low cost of oral disintegrating tablets have increased the preference for ODTs in the region.

The orally disintegrating tablets market in North America is expected to grow at a significant pace during the forecast period, owing to the rise in prevalence of diseases associated with the CNS. Alzheimer's disease, Bell's palsy, epilepsy, and Parkinson's disease are some CNS diseases.

According to Alzheimer's Association a voluntary health organization in Alzheimer's care, an estimates 5.8 Million people in the US, aged 65 and above are suffering from Alzheimer's disease in 2020, and this number is anticipated to reach by 13.8 Million by 2050. Growing adoption of technologically advanced products is boosting the growth of the market in the region. Moreover, presence of key market players in the region is expected to boost the market in North America during the forecast period.

Get Free Sample Report

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the ODT market.
• Historical, Current and Projected Market Size in terms of Value.
• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
• Industry Drivers, Restraints and Opportunities Covered in the Study
• Recent Industry Trends and Developments
• Competitive Landscape & Strategies of Key Players
• Neutral Perspective on Global ODT market Performance